Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 924-933

  Lanz, Thomas A ^a   Karmilowicz, Michael J ^a   Wood, Kathleen M ^a   Pozdnyakov, Nikolay ^a   Du, Ping ^a   Piotrowski, Mary A ^a   Brown, Tracy M ^a   Nolan, Charles E ^a   Richter, Karl E G ^a   Finley, James E ^a   Fei, Qing ^a   Ebbinghaus, Charles F ^a   Chen, Yuhpyng L ^a   Spracklin, Douglas K ^a   Tate, Barbara ^a   Geoghegan, Kieran F ^a   Lau, Lit Fui ^a   Auperin, David D ^a   Schachter, Joel B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 3 METHYL N [1 (3 METHYL 2 OXO 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 CARBAMOYL)ETHYL]BUTYRAMIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE INHIBITOR; LY 450139; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EMBRYONIC STEM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STEADY STATE;

ALANINE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AZEPINES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GUINEA PIGS; MALE; MICE; TIME FACTORS;

EID: 33751174340     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.110700     Document Type: Article

References (28)

1. Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, et al. (2005) Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69:689-698.
2. Barten DM, Guss VL, Corsa JA, Loo AT, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al. (2005) Dynamics of β-amyloid reductions in brain, cerebrospinal fluid and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 312:635-643.
3. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, and Shearman MS (2005) Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 279:43419-43426.
4. Best JD, Jay MT, Otu F, Churcher I, Reilly M, Morentin-Gutierrez P, Pattison C, Harrison T, Shearman MS, and Atack JR (2006) In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel γa-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2, 5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 317:786-790.
5. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Investig 115:3285-3290.
6. Cirrito JR, May PC, O'Dell MA, Taylor JT, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23:8844-8853.
7. Coolen MW, van Loo KM, van Bakel NN, Ellenbroek BA, Cools AR, and Martens GJ (2006) Reduced Aph-1b expression causes tissue- and substrate-specific changes in γ-secretase activity in rats with a complex phenotype. FASEB J 20:175-177.
8. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
9. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. (2001) Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 76:173-181.
10. El Mouedden M, Vandermeeren M, Meert T, and Mercken M (2006) Reduction of Aβ levels in the Sprague Dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: a novel non-transgenic model for Aβ production inhibitors. Curr Pharm Des 12:671-676.
11. Fraering PC, Ye W, LaVoie MJ, Ostaszewski BJ, Selkoe DJ, and Wolfe MS (2005) γ-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 280:41987-41996.
12. German DC and Eisch AJ (2004) Mouse models of Alzheimer's disease: insight into treatment. Rev Neurosci 15:353-369.
13. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, et al. (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat Cell Biol 11:1118-1123.
14. Hyslop PA, May PC, Audia JE, Calligaro DO, McMillian CL, Garner CO, Cramer JW, Gitter BD, Porter WJ, and Nissen JS (2004) Reduction in A-β(1-40) and A-β(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139. Neurobiol Aging 25:S147.
15. Johnstone EM, Chaney MO, Norris FH, Pascual R, and Little SP (1991) Conservation of the sequence of Alzheimer's disease amyloid peptide in dog, polar bear, and five other mammals by cross-species polymerase chain reaction analysis. Mol Brain Res 10:299-305.
16. Kornilova AY, Bihel F, Das C, and Wolfe MS (2005) The initial substrate-binding site of γ-secretase is located on presenilin near the active site. Proc Natl Acad Sci USA 102:3230-3235.
17. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, and Merchant KM (2003) The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L- alanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305:864-871.
18. 1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl] -L-alaninamide (LY-411575). J Pharmacol Exp Ther 309:49-55.
19. Lanz TA and Schachter JB (2006) Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-β from wild type rodent brain. J Neurosci Methods 157:71-81.
20. Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, Pauley AM, Himes CS, Qin W, Kola I, et al. (2003) Positive and negative regulation of the γa-secretase activity by nicastrin in a murine model. J Biol Chem 278:33445-33449.
21. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, and Wiskniewski HM (1998) Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci Lett 241:13-16.
22. Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, and Ihara Y (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid β-protein 42 in Chinese hamster ovary cells. Biochemistry 42:1042-1052.
23. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, et al. (2005) Longer forms of amyloid β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 25:436-445.
24. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, and May PC (2005) Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126-132.
25. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (Lond) 414:212-216.
26. Wood KM, Du P, Geoghegan KF, and Tate B (2005) In vivo Aβ peptide profiling by immunoprecipitation and mass spectroscopy. In Proceedings of the Annual Meeting of the Society for Neuroscience; 2005 Nov 12-16; Washington, DC.
27. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, et al. (2004) Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882.
28. Yagashita S, Morishima-Kawashima M, Tanimura Y, Ishiura S, and Ihara Y (2006) DAPT-induced intracellular accumulations of longer amyloid γ-proteins: further implications for the mechanism of intramembrane cleavage by γ-secretase. Biochemistry 45:3952-3960.